Comparative Pharmacology
Head-to-head clinical analysis: BISMUTH SUBSALICYLATE METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus RETET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISMUTH SUBSALICYLATE METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus RETET.
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE vs RETET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bismuth subsalicylate exerts antimicrobial and anti-inflammatory effects via binding to gastrointestinal mucosa and inhibiting prostaglandin synthesis; metronidazole inhibits DNA synthesis by forming nitro radical anions; tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
RETET is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors, thereby blocking estrogen-mediated signaling in target tissues.
Each dose consists of 2 capsules (each containing bismuth subsalicylate 262.4 mg, metronidazole 250 mg, and tetracycline hydrochloride 375 mg) taken orally 3 times daily (after meals) for 10 days.
No standard dosing available; RETET is not a recognized therapeutic agent. Please verify drug name.
None Documented
None Documented
Bismuth subsalicylate: Bismuth component ~5 days (accumulation risk), salicylate 2–3 hours; Metronidazole: 8 hours (increased in hepatic impairment); Tetracycline HCl: 6–12 hours (prolonged in renal impairment).
Terminal elimination half-life 18-24 hours in healthy adults; prolonged to 30-40 hours in moderate renal impairment (CrCl 30-50 mL/min).
Bismuth subsalicylate: Renal excretion of salicylate and bismuth (bismuth largely fecal as insoluble sulfide); Metronidazole: Renal 60–80% (unchanged and metabolites), fecal 6–15%; Tetracycline HCl: Renal 60% unchanged, fecal 40% (biliary and direct excretion).
Renal: 70-80% unchanged; Fecal: 10-15%; Biliary: <5%.
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic